How Antibiotic Resistance Emerges and What Stewardship Actually Does

Antibiotic resistance is not a mysterious force. It emerges through ordinary natural selection: an antibiotic kills the susceptible bacteria in a population and leaves the few resistant survivors behind to multiply and pass their resistance genes onward. Every exposure, warranted or not, applies that selection pressure, which is why overuse accelerates a problem that already exists in nature. Stewardship is the disciplined effort to give antibiotics only when they help and only for as long as they help, and the controlled evidence shows it reduces inappropriate use and shortens treatment without increasing deaths.

The mechanism: selection, not creation

A common misconception is that antibiotics cause bacteria to become resistant. They do not manufacture resistance; they select for it. Resistance genes predate modern medicine by millions of years, and some have been recovered from soil bacteria in isolated caves untouched by pharmaceuticals. In any large bacterial population, random mutation and pre-existing genetic variation mean a handful of cells can already survive a given drug.

When an antibiotic is introduced, the vulnerable cells die and the resistant ones inherit the field. They then reproduce, sometimes within hours, and can hand their resistance traits to unrelated bacteria through horizontal gene transfer, often carried on mobile loops of DNA called plasmids. That sharing is why resistance to one drug can spread across species and why a resistance trait acquired in one setting can surface in another. The more often and less precisely we deploy antibiotics, the more we tilt this selective process in favor of the survivors.

How the CDC ranks the threats

The U.S. Centers for Disease Control and Prevention organizes the danger into a tiered framework in its 2019 Antibiotic Resistance Threats Report, sorting pathogens by clinical and public health impact into urgent, serious, and concerning categories, plus a watch list for emerging threats.

The five urgent threats are carbapenem-resistant Acinetobacter, drug-resistant Candida auris, Clostridioides difficile, carbapenem-resistant Enterobacterales, and drug-resistant Neisseria gonorrhoeae. Serious threats include MRSA, vancomycin-resistant Enterococcus, extended-spectrum beta-lactamase-producing Enterobacterales, multidrug-resistant Pseudomonas aeruginosa, and drug-resistant tuberculosis, among others. The concerning tier covers erythromycin-resistant Group A Streptococcus and clindamycin-resistant Group B Streptococcus, while the watch list flags threats such as azole-resistant Aspergillus fumigatus and Mycoplasma genitalium.

The scale is substantial. The CDC estimates more than 2.8 million antimicrobial-resistant infections occur in the United States each year, causing more than 35,000 deaths. When C. difficile, which is closely tied to antibiotic use, is included, the annual toll rises above 3 million infections and 48,000 deaths. Globally, a 2022 analysis in The Lancet attributed roughly 1.27 million deaths directly to bacterial resistance in 2019 and associated it with nearly 5 million. More recent CDC surveillance covering 2021 and 2022, published in 2024, found that several hospital-onset resistant infections rose by a combined 20 percent during the COVID-19 pandemic compared with the years before it, and that C. auris clinical cases increased nearly fivefold from 2019 to 2022. These figures are estimates drawn from surveillance systems and modeling, not a perfect census, and the CDC describes them as conservative.

What stewardship actually does

Antibiotic stewardship is a set of coordinated practices meant to improve how these drugs are prescribed. The rationale is straightforward once the mechanism is clear: less unnecessary exposure means less selection pressure. The CDC estimates that at least 30 percent of antibiotics prescribed in outpatient settings are unnecessary, with further opportunities to improve the selection, dose, and duration of the rest.

The CDC frames stewardship around Core Elements. Its 2016 Core Elements of Outpatient Antibiotic Stewardship, published in MMWR, describes four practical commitments: leadership commitment to appropriate use, action such as adopting evidence-based prescribing guidance, tracking and reporting of prescribing patterns, and clinician and patient education. In hospitals, common interventions include prospective audit with feedback, in which a pharmacist or specialist reviews prescriptions and suggests adjustments, and preauthorization requirements for restricted agents.

How the evidence base is built

Judging whether these interventions work is a methodological problem, not a matter of opinion. The most comprehensive synthesis is a Cochrane systematic review of interventions to improve antibiotic prescribing for hospital inpatients, which pooled more than 200 studies. Its authors concluded that stewardship interventions increase compliance with prescribing policy, reduce the duration of antibiotic treatment, and shorten hospital length of stay, and that they do so without increasing mortality.

That last point is what makes the evidence persuasive. A responsible evaluation cannot only measure whether prescribing dropped, because prescribing could be cut in ways that harm patients. Strong stewardship studies therefore track balancing measures, chiefly death and readmission, to confirm that reducing antibiotics did not trade safety for tidiness. The review distinguished restrictive strategies, which constrain what clinicians can order, from enabling strategies such as audit and feedback, and it drew on a mix of randomized trials and interrupted time-series designs. Interrupted time-series analysis matters here because randomizing individual patients to receive worse prescribing is often impractical, so researchers compare trends before and after an intervention while accounting for pre-existing direction. Reading these studies well means separating process measures, such as whether prescribing changed, from clinical outcomes, such as whether patients did as well or better.

What this means for readers

Understanding the mechanism reframes familiar advice. Resistance is a shared resource problem: each unnecessary course nudges the collective ecology of bacteria, even when an individual feels no immediate effect. Research increasingly supports shorter, targeted courses for many common infections rather than the reflexive assumption that longer is always safer, though the right choice depends on the specific infection and belongs to the treating clinician. Pressuring a clinician for antibiotics to treat a viral illness, where they do no good, is one of the clearest ways ordinary decisions feed a population-level problem. This article is educational and not a substitute for individual medical advice.